Navigation Links
AlphaRx Unveils its China Strategy
Date:7/21/2009

    AlphaRx plans to open an R&D facility and manufacturing plant in China
    with local partners, to introduce innovative drug products to the fastest
    growing pharmaceutical market in the world.

MARKHAM, ON, July 21 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company, utilizing proprietary drug delivery technology to develop novel formulations of drugs, is forging ahead with its growth strategy for Greater China. As part of this strategy, AlphaRx is poised to open a "state of the art" R D and pilot plant facility in China with local partners. The R D facility will focus on the development of innovative drug products targeting infectious disease and various forms of cancer. Additionally, the Company, together with its local partners, plans to develop adjuvant vaccines to treat influenza, such as H5N1 and H1N1 strains.

AlphaRx currently has a topical NSAID awaiting near-term registration in China and is developing a second product - GAI-122 - an injectable nanoemulsion, in collaboration with Gaia BioPharma for the treatment of acute hepatitis, a therapy with a multi-million dollar potential indication in China.

The Chinese government has been a strong supporter of the life sciences industry. It plans to further increase its investment in the sector through a variety of grants and awards in some of its leading science and technology parks and through the National Program 863, originally established in March 1983 by Deng Xiaoping to award grants to science and technology projects that have significant commercial value. Most notably, in November 2008, China launched the Mega New Drug Development Program, a plan to invest $10 billion over the next 13 years, with the aim of creating a China-based innovative drug development industry.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
2. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
3. AlphaRx Shareholder Update
4. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
5. AlphaRx Signs Cooperative Research and Development Agreement with US Army
6. AlphaRx Provides Corporate and Development Update
7. AlphaRxs Indaflex(TM) Continues its Clinical Development
8. AlphaRx CEO Accumulates More Company Shares
9. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
10. AlphaRx Announces Debt Conversion
11. AlphaRx To Present at 47th Annual ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
Breaking Medicine Technology: